Boehringer Ingelheim and Simcere are agreeing to develop SIM0709, a pre-clinical bispecific antibody, for treatment of inflammatory bowel disease (IBD). Boehringer Ingelheim receives global rights to the asset outside of greater China. Originally developed by Simcere, SIM0709 simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23). As such, the TL1A/IL23p19 antibody blocks two core pathways that drive onset and progression of IBD. In&nbsp...